Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like New target identified for potential ALS therapy September 10, 2024 CPAP therapy may not reduce heart risks in sleep apnea patients with coronary artery disease January 29, 2024 Hamster sera study reveals Omicron subvariants’ vast antigenic diversity July 31, 2024
CPAP therapy may not reduce heart risks in sleep apnea patients with coronary artery disease January 29, 2024